DEF 14A: Scorpius Holdings Seeks Stockholder Approval for Reverse Stock Split, Incentive Plan Amendment, and Note Conversion

Scorpius Holdings is asking stockholders to approve a reverse stock split, an amendment to its stock incentive plan, and the conversion of a promissory note at its upcoming annual meeting.

Summary

• Scorpius Holdings is holding its 2024 Annual Meeting of Stockholders on July 15, 2024, to vote on several key proposals.
• The proposals include the election of four directors, ratification of the appointment of BDO USA, P.C. as the independent auditor, and an amendment to the 2018 Stock Incentive Plan to increase the number of shares available by 30,000,000.
• Stockholders will also vote on a reverse stock split proposal, with a ratio ranging from 1-for-5 to 1-for-200, to be determined by the Board of Directors.
• Another proposal involves approving the issuance of up to 20,781,771 shares of Common Stock to Elusys Holdings Inc. upon conversion of a convertible promissory note.
• The meeting will also address an adjournment proposal to allow for further solicitation of votes if necessary.
• The Board of Directors recommends voting FOR all nominees and proposals.

Sentiment

Score: 4

Explanation: The document outlines necessary corporate actions, but the potential delisting and need for a reverse stock split suggest underlying financial challenges.

Positives

• The reverse stock split aims to increase the per-share trading price and regain compliance with NYSE American requirements.
• Increasing shares under the 2018 Plan will help attract, retain, and motivate employees, directors, and consultants.
• Converting the note to Elusys Holdings could preserve cash by repaying debt with share issuances.

Negatives

• The reverse stock split could decrease the liquidity of the Common Stock.
• The reverse stock split may result in some stockholders owning odd lots that may be more difficult to sell or require greater transaction costs per share to sell.
• The reverse stock split may lead to a decrease in the overall market capitalization of the company.
• The reverse stock split may lead to further dilution of the Common Stock.
• Approval of the note conversion proposal will result in dilution for existing shareholders.

Risks

• The reverse stock split may not result in a sustained increase in the price of the Common Stock.
• The NYSE American has suspended trading of the company's common stock and commenced delisting proceedings.
• The company may not be able to permit the conversion of the Restated Note, and therefore, would be required to repay all outstanding amounts under the Restated Note in cash at maturity if the note conversion proposal is not approved.

Future Outlook

The company intends to appeal the NYSE Regulations determination to delist its Common Stock. The company may seek a listing on another national securities exchange if it is not successful in its appeal with the NYSE American.

Industry Context

The document does not provide specific industry context beyond the company's need to maintain its listing on a national securities exchange and attract investors.

Related Party Transactions

• The company completed the sale of Elusys Therapeutics to Elusys Holdings Inc., a company controlled by Jeffrey Wolf, for $500,000 plus assumption of certain liabilities and manufacturing commitments.
• The company issued a convertible promissory note to Elusys Holdings Inc. in the principal amount of $2,250,000.
• Jeffrey Wolf purchased 2,500,000 units in the public offering consummated by the company on May 16, 2024.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution, changes in stock price, and voting rights.
• Employees may be affected by changes to the stock incentive plan.
• The reverse stock split could affect the marketability of existing shares.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on July 15, 2024.
• The Board of Directors will determine whether and when to effect the reverse stock split based on market conditions and other factors.
• The company intends to appeal the NYSE Regulations determination to delist its Common Stock.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, stock incentive plan, note conversion, Scorpius Holdings, BDO USA, directors, Elusys Holdings, common stock